

# Impfprävention

Ralph Köllges

## Literatur:

1. Roupheal NG, Stephens DS (2012) *Neisseria meningitidis*: biology, microbiology, and epidemiology. *Methods Mol Biol.* 799: 1–20
2. Purmohamad A, Abasi E, Azimi T, Hosseini S, Safari H et al. (2019) Global estimate of *Neisseria meningitidis* serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis. *Microbial Pathogenesis* 134 103571
3. Mbaeyi S, Duffy J, McNamara LA (2024) CDC. *Epidemiology and Prevention of Vaccine-Preventable Diseases, Pink Book. Chapter 14 Meningococcal Disease*
4. Borrow R, Alarcón P, Carlos J, Caugant DA, Cristensen H et al. (2017), The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. *Expert Rev Vaccines* 16: 313–328
5. Christensen H, May M, Bowen L, Hickman M, Trotter CL (2010) Meningococcal carriage by age: a systematic review and meta-analysis. *Lancet Infect Dis* 10(12): 853–861
6. Yazdankhah SP, Caugant DA (2004) *Neisseria meningitidis*: an overview of the carriage state. *J Med Microbiol* 53: 821–832
7. Koch-Institut R, *Epid. Bulletin* 14/2022, S. 63
8. MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC et al. (2006) Social behavior and meningococcal carriage in British teenagers. *Emerg Infect Dis* 12(6): 950–970
9. Koch-Institut R, *Ratgeber für Ärzte: Meningokokken-Erkrankungen*. 18.06.2015
10. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughs JM (2001) Meningococcal Disease. *N Engl J Med* 344: 1378–1388
11. Koch-Institut R, *Ratgeber für Ärzte Meningokokken-Erkrankungen* 18.06.2015
12. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughs JM (2001) Meningococcal Disease. *N Engl J Med* 344:1378–1388
13. EU Clinical Trials Register. 2016-000749-30 (MET51) results summary. November 2018. Available at: <https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000749-30/results> [accessed September 2020]
14. Baccarini CI, Simon MW, Brandon D, Christensen S, Jordanov E et al. (2020) Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study. *Pediatr Infect Dis J.*

15. Chang LJ, Hedrick J, Christensen S, Pan J, Jordano E et al. (2020) A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. *Vaccine* 38(19): 3560–3569
16. Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D et al. (2020) Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study. *Vaccine* 38(33): 5194–5201
17. Esteves-Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E et al. (2020) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study. *Vaccine* 38(28): 4405–4411
18. Áñez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R et al. (2020) Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study. *Hum Vaccin Immunother.* 16(6):1292–1298
19. Kirstein J, Pina M, Pan J, Jordanov E, Dhingra MS (2020) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. *Hum Vaccin Immunother.* 16(6): 1299–1305
20. Díez-Domingo J, Simkó R, Icardi G, Chong CP, Zocchetti C et al. (2024) Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study. *Infect Dis. Ther.* 13:1835–1859
21. US ClinicalTrials.gov Identifier: NCT04490018 (MEQ00071) (2023) Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents. Available at <https://clinicaltrials.gov/study/NCT04490018?cond=NCT04490018&rank=1&tab=results>[Accessed December 2024]
22. Koch-Institut R, *Epid. Bulletin* Nr. 31, 4. August 2006
23. Koch-Institut R, *Epid. Bulletin* Nr. 32, 13. August 2012
24. Koch-Institut R, *Epid. Bulletin* 44/2025 30. Oktober 2025
25. Kinder- und Jugendärzte\* in Heft 01/26